

1. NAME OF THE MEDICINAL PRODUCT

ALPHA BETA ARTEETHER INJECTION 75MG/ML
INJECTION

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml contains:

$\alpha - \beta$ Arteether IH ... 75 mg

Arachis Oil BP QS.

{For a full list of excipients, see section 6.1}

3. PHARMACEUTICAL FORM

A light-yellow coloured, clear solution

4. Clinical particulars

4.1 Therapeutic indications

Severe malaria including cerebral malaria and as a second line drug in chloroquine resistant malaria cases only.

4.2 Posology and method of administration

$\alpha - \beta$ Arteether Injection is for intramuscular use only.

Adult: 150 mg i.e. 1 ampoules once daily for 3 consecutive days

Children - 3mg/Kg per day administered by intramuscular injection over a 3-day period The injection must be given under aseptic conditions, deep intramuscularly in the upper lateral quadrant of the buttock. No other drug should be mixed in the same syringe.

4.3 Contraindications

$\alpha - \beta$ Arteether injection is contraindicated in patients hypersensitive to artemisinin derivatives or any of the excipients.

4.4 Special warnings and precautions for use

When treating children, particular care should be taken to ensure the correct doses are given and retained.

4.5 Interaction with other medicinal products and other forms of interaction

Prolonged QT interval has been reported in some studies with high dosage of artemisinin derivatives. The cardiac effects of artemisinins are not very important from a clinical point of view, except that caution should be exercised against combinations with other drugs that prolong the QT interval, such as quinine and halofantrine.

4.6 Pregnancy and Lactation

Pregnancy

Adequate studies regarding safe use of artemisinin derivatives during pregnancy are not available. Artemisinin derivatives should not be used in pregnancy as primary drugs for uncomplicated malaria cases but these can be used for treatment of severe or complicated *P. falciparum* malaria infection in patients of multiple drug resistance, if the benefits justify the potential risk to the fetus.

Nursing Mother

It is not known whether α - β Arteether is secreted in human milk. Because many drugs are secreted in human milk caution should be exercised while using α - β Arteether.

4.7 Effects on ability to drive and use machines

Not Known.

4.8 Undesirable effects

While neurotoxicity has been reported in experimental animals, there is no evidence of neurotoxicity in human beings with artemisinin derivatives. α - β Arteether is usually well tolerated. However, nausea, dizziness and depressed GIT activity can occur. Clinical, neurological, electrocardiographic and biochemical monitoring did not reveal significant toxicity. Apart from some increase in eosinophil numbers, no haematological abnormality was seen.

4.9 Overdose

Overdose treatment should be symptomatic and supportive

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamics properties

Pharmacotherapeutic group: Antimalarial

ATC code: P01BE

Mechanism of action:

α - β Arteether is a fast-acting blood schizonticidal agent for *P. falciparum* malaria at the erythrocytic stage.

α - β Arteether is concentrated in parasitized erythrocytes. The functional group responsible for antimalarial activity of α - β Arteether is endoperoxide bridge. Iron from the digested haemoglobin of the parasite's victim reduces this bridge, releasing a highly reactive free radical iron species which causes lysis of the parasitic cell. It is also proposed that α - β Arteether inhibits the protein synthesis and alters the ribosomal organization and endoplasmic reticulum.

5.2 Pharmacokinetic properties

α - β Arteether is transformed into dihydroartemisinin. It has a half-life of 20 hours. It is eliminated by hepatic metabolism. The elimination is much slower compared to other artemisinin compounds.

5.3 Preclinical safety data

Preclinical studies of arteether injection have been completed. No intolerance has yet been observed.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Benzyl Alcohol BP

Tocopheryl Acetate BP

Arachis Oil BP

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

24 months from the date of manufacturing.

Use immediately after opening, any unused portion should be discarded.

6.4 Special precautions for storage.

Store in a cool & dry place below 30°C. Protect from Light.

Keep all medicines out of the reach of children.

6.5 Nature and contents of container

3 x 2ml, Amber, Blue Dot OPC Glass Ampoule.

6.6 Special precautions for disposal and other handling

Any unused portion should be discarded as per local regulations

7. Applicant:

KARIFIELD PHARMACEUTICAL
LIMITED, RAJI RASAKI ROAD
AMUWU ODOFIN, LAGOS.

Manufacturer:

FARBE FIRMA PRIVATE
LIMITED, Plot No, 1508,
GIDC, ANKLESHWAR
393002, GUJARAT, INDIA.